Changchun High-tech (000661.SZ) subsidiary Jinsai Pharmaceutical has reached a cooperation agreement with Denmark's ALK on allergen-specific immunotherapy products.

Zhtng cijng APP xn, chngchn goxn (000661.SZ) gnggo, gngs kngg zgngschngchn jnsi yoy yuxin zrn gngs (jinchng jnsi yoy) y dnmi ALK-AbellA/S gngs (jinchng ALK) ddo bin yngyun tsuy xng min y zhlio (AIT) chnpn hzu, jing zi zhnggu linh kif bng shngyhu ALK de w chn mn (HDM) bin yngyun tsuy xng min y zhlio chnpn, bng hud ALK zzh kif de 3 kun chnpn zi zhnggu dl fnwi ni de dji dil qun y. ChiNext Financial News APP, Changchun High-tech (000661.SZ) announced that the company's controlling subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has reached a cooperation agreement with Denmark's ALK-Abell A/S (referred to as "ALK") on allergen-specific immunotherapy (AIT) products. The two companies will jointly develop and commercialize ALK's house dust mite (HDM) allergen-specific immunotherapy products in China, and will obtain exclusive agency rights for three products developed independently by ALK in mainland China.